Form 4: IDEAYA Biosciences Director Acquires Stock Options

IDEAYA Biosciences, Inc. reports that Director Terry J. Rosen acquired 20,000 stock options with an exercise price of $30.57.

Summary

• Director Terry J. Rosen of IDEAYA Biosciences, Inc. was granted 20,000 stock options on June 16, 2026.
• The options have an exercise price of $30.57 and an expiration date of June 16, 2036.
• These options represent the right to buy common stock.
• The vesting schedule indicates that 100% of the shares subject to the option will vest on the earlier of the first anniversary of the grant date or immediately prior to the Annual Meeting following the grant date, provided the Reporting Person continues to serve on the Board.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates director commitment through option acquisition, but it does not provide new financial performance data.

Positives

• Director acquisition of stock options signals confidence in the company's future prospects.
• The vesting schedule aligns the director's incentives with long-term company performance.

Future Outlook

The vesting schedule for the stock options suggests a forward-looking perspective tied to continued service and company performance.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology sector, aligning executive incentives with shareholder value and reflecting management's commitment to the company's long-term growth.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as a sign of commitment and alignment of interests.

Next Steps

• Vesting of stock options based on continued service and company meeting schedule.

Key Dates

Keywords

IDEAYA Biosciences, IDYA, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act